13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
49 檔
54.7%
According to the latest 13F quarterly dataset, Artia Global Partners LP managed an equity portfolio of $541.9M at the end of Q1 2026, spanning 49 distinct U.S. exchange-listed positions.
Artia Global Partners LP executed strategic sector rebalancing during Q1 2026, establishing 11 new positions while fully exiting 12 holdings and trimming 11 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 29.74% | -18.15% | -17.58% | |
| 2 | ABVX | Abivax Sa-adr | Stock-Other | 13.39% | -0.69% | -1.62% | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 7.04% | -7.04% | EXIT | |
| 4 | TRVI | Trevi Therapeutics Inc | Stock-Other | 4.81% | +2.80% | — | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.35% | +0.74% | -54.03% | |
| 6 | AZN | AstraZeneca PLC | Stock-Healthcare | 3.77% | -0.33% | — | |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.23% | -0.08% | — | |
| 8 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.74% | +0.19% | -20.53% | |
| 9 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.43% | +3.98% | +19.96% | |
| 10 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.17% | -0.06% | — | |
| 11 | MRNA | Moderna Inc | Stock-Healthcare | 2.03% | -2.03% | EXIT | |
| 12 | EYPT | Eyepoint Inc | Stock-Other | 1.98% | +0.04% | — | |
| 13 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 1.60% | +0.95% | — | |
| 14 | ALMS | Alumis Inc | Stock-Other | 1.43% | +0.02% | — | |
| 15 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.18% | +0.12% | -74.88% | |
| 16 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.12% | -0.01% | — | |
| 17 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.11% | -1.11% | EXIT | |
| 18 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.11% | -0.05% | — | |
| 19 | SION | Sionna Therapeutics Inc | Stock-Other | 0.96% | +0.01% | — | |
| 20 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.95% | +0.03% | — | |
| 21 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.87% | +0.20% | — | |
| 22 | ASND | Ascendis Pharma A/S | Stock-Other | 0.81% | -0.81% | EXIT | |
| 23 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.80% | -0.09% | +38.91% | |
| 24 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.76% | -0.04% | +62.50% | |
| 25 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.75% | -0.06% | — | |
| 26 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.72% | +0.13% | — | |
| 27 | PALI | Palisade Bio Inc | Stock-Other | 0.70% | +0.07% | — | |
| 28 | BIIB | Biogen Inc | Stock-Healthcare | 0.68% | +0.06% | — | |
| 29 | PROK | Prokidney CORP | Stock-Other | 0.65% | +0.03% | -1.71% | |
| 30 | ABBV | Abbvie Inc | Stock-Healthcare | 0.63% | -0.63% | EXIT | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.59% | -0.09% | — | |
| 32 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.56% | -0.06% | +14.97% | |
| 33 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.48% | +0.04% | -0.09% | |
| 34 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.46% | -0.46% | EXIT | |
| 35 | BTSG | Brightspring Health Services | Stock-Other | 0.46% | +6.20% | +29.33% | |
| 36 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.42% | +3.13% | — | |
| 37 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.41% | +0.33% | — | |
| 38 | CELC | Celcuity Inc | Stock-Other | 0.36% | +0.79% | +20.74% | |
| 39 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.30% | -0.30% | EXIT | |
| 40 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.28% | +0.06% | — | |
| 41 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.22% | +0.89% | — | |
| 42 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.16% | +0.52% | — | |
| 43 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.16% | -0.01% | — | |
| 44 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.13% | -0.02% | — | |
| 45 | KOD | Kodiak Sciences Inc | Stock-Other | 0.13% | -0.01% | — | |
| 46 | NUVL | Nuvalent Inc-a | Stock-Other | 0.10% | +0.01% | -39.51% | |
| 47 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.10% | -0.10% | EXIT | |
| 48 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.09% | -0.09% | EXIT | |
| 49 | PEPG | Pepgen Inc | Stock-Other | 0.07% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +2.6% | -17.58% | Trim |
| 2 | ABVX | Abivax Sa-adr | +1.7% | -1.62% | Trim |
| 3 | DNTH | Dianthus Therapeutics Inc | +1.5% | -20.53% | Trim |
| 4 | RVMD | Revolution Medicines Inc | +1.3% | +19.96% | Add |
| 5 | TRVI | Trevi Therapeutics Inc | +1.2% | — | Unchanged |
| 6 | NAMS | NewAmsterdam Pharma Company N.V. | +0.7% | — | Unchanged |
| 7 | DGX | Quest Diagnostics Inc | +0.6% | — | Unchanged |
| 8 | IONS | Ionis Pharmaceuticals Inc | +0.6% | — | Unchanged |
| 9 | XENE | Xenon Pharmaceuticals Inc | +0.5% | +62.50% | Add |
| 10 | BLTE | Belite Bio Inc - Adr | +0.4% | +38.91% | Add |
| 11 | SRRK | Scholar Rock Holding CORP | +0.4% | — | Unchanged |
| 12 | ROIV | Roivant Sciences Ltd. | +0.3% | — | Unchanged |
| 13 | ASND | Ascendis Pharma A/S | +0.3% | — | Unchanged |
| 14 | RAPP | Rapport Therapeutics Inc | +0.3% | — | Unchanged |
| 15 | SION | Sionna Therapeutics Inc | +0.3% | — | Unchanged |
| 16 | BTSG | Brightspring Health Services | +0.2% | +29.33% | Add |
| 17 | UTHR | United Therapeutics CORP | +0.2% | — | Unchanged |
| 18 | PTGX | Protagonist Therapeutics Inc | +0.2% | -0.09% | Trim |
| 19 | DRUG | Bright Minds Biosciences Inc | +0.2% | +14.97% | Add |
| 20 | CELC | Celcuity Inc | +0.2% | +20.74% | Add |
| 21 | ABBV | Abbvie Inc | +0.2% | — | Unchanged |
| 22 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | — | Unchanged |
| 23 | BBIO | Bridgebio Pharma Inc | +0.1% | — | Unchanged |
| 24 | PROK | Prokidney CORP | +0.1% | -1.71% | Trim |
| 25 | KOD | Kodiak Sciences Inc | +0.1% | — | Unchanged |
| 26 | TENX | Tenax Therapeutics Inc | +0.1% | — | Unchanged |
| 27 | PRAX | Praxis Precision Medicines I | +0.1% | — | Unchanged |
| 28 | MLYS | Mineralys Therapeutics Inc | 0% | — | Unchanged |
| 29 | PALI | Palisade Bio Inc | 0% | — | Unchanged |
| 30 | TVTX | Travere Therapeutics Inc | 0% | — | Unchanged |
| 31 | EYPT | Eyepoint Inc | 0% | — | Unchanged |
| 32 | AVTX | Avalo Therapeutics Inc | 0% | -30.31% | Trim |
| 33 | NUVL | Nuvalent Inc-a | 0% | -39.51% | Trim |
| 34 | PEPG | Pepgen Inc | -0.1% | — | Unchanged |
| 35 | LLY | Eli Lilly & Co | -0.7% | -24.32% | Trim |
| 36 | VKTX | Viking Therapeutics Inc | -2.4% | -74.88% | Trim |
| 37 | ARGX | Argenx Se - Adr | -3.4% | -54.03% | Trim |
| 38 | SLNOEUR | Soleno Therapeutics Inc | -3.4% | -88.27% | Trim |
| 39 | UGL | Proshares Ultra Gold | — | EXIT | Sold out |
| 40 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 41 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 42 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 43 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 44 | MRNA | Moderna Inc | — | NEW | New buy |
| 45 | ALMS | Alumis Inc | — | NEW | New buy |
| 46 | ALNY | Alnylam Pharmaceuticals Inc | — | EXIT | Sold out |
| 47 | VTYXUSD | Ventyx Biosciences Inc | — | EXIT | Sold out |
| 48 | PVLA | Palvella Therapeutics Inc | — | EXIT | Sold out |
| 49 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 50 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 49 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, ABVX, LLY) accounted for 54.7% of total reported equity market value during Q1 2026.
Top New Position Initiated
AZN
市值: $18.8M
Top Position Liquidated / Trimmed
UGL
前期市值: $30.1M
During Q1 2026, Artia Global Partners LP's top holdings by market value included INSM (29.7%)、ABVX (13.4%)、LLY (7.0%). The largest single position, INSM, represented 29.7% of total portfolio value.
In Q1 2026, Artia Global Partners LP made 40 total portfolio adjustments, initiating 11 new buys, adding to 6 positions, trimming 11 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.